WallStSmart

Nebius Group N.V. (NBIS)vsSanofi ADR (SNY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Sanofi ADR generates 5294% more annual revenue ($47.35B vs $877.90M). NBIS leads profitability with a 93.1% profit margin vs 16.0%. NBIS appears more attractively valued with a PEG of 0.63. NBIS earns a higher WallStSmart Score of 53/100 (C-).

NBIS

Buy

53

out of 100

Grade: C-

Growth: 8.0Profit: 5.0Value: 6.7Quality: 5.5
Piotroski: 5/9Altman Z: 0.92

SNY

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 6.5Value: 5.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NBISUndervalued (+33.0%)

Margin of Safety

+33.0%

Fair Value

$309.18

Current Price

$221.15

$88.03 discount

UndervaluedFair: $309.18Overvalued
SNYUndervalued (+24.9%)

Margin of Safety

+24.9%

Fair Value

$62.64

Current Price

$42.50

$20.14 discount

UndervaluedFair: $62.64Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NBIS4 strengths · Avg: 9.3/10
Profit MarginProfitability
93.1%10/10

Keeps 93 of every $100 in revenue as profit

Revenue GrowthGrowth
621.0%10/10

Revenue surging 621.0% year-over-year

Market CapQuality
$52.63B9/10

Large-cap with strong market position

PEG RatioValuation
0.638/10

Growing faster than its price suggests

SNY4 strengths · Avg: 8.8/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

Market CapQuality
$102.26B9/10

Large-cap with strong market position

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$1.68B8/10

Generating 1.7B in free cash flow

Areas to Watch

NBIS4 concerns · Avg: 3.3/10
Price/BookValuation
12.3x4/10

Trading at 12.3x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Debt/EquityHealth
1.063/10

Elevated debt levels

P/E RatioValuation
80.0x2/10

Premium valuation, high expectations priced in

SNY3 concerns · Avg: 2.3/10
Return on EquityProfitability
6.6%3/10

ROE of 6.6% — below average capital efficiency

PEG RatioValuation
3.712/10

Expensive relative to growth rate

EPS GrowthGrowth
-11.7%2/10

Earnings declined 11.7%

Comparative Analysis Report

WallStSmart Research

Bull Case : NBIS

The strongest argument for NBIS centers on Profit Margin, Revenue Growth, Market Cap. Profitability is solid with margins at 93.1% and operating margin at -32.1%. Revenue growth of 621.0% demonstrates continued momentum.

Bull Case : SNY

The strongest argument for SNY centers on Price/Book, Market Cap, Operating Margin. Profitability is solid with margins at 16.0% and operating margin at 20.0%.

Bear Case : NBIS

The primary concerns for NBIS are Price/Book, EPS Growth, Debt/Equity. A P/E of 80.0x leaves little room for execution misses.

Bear Case : SNY

The primary concerns for SNY are Return on Equity, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

NBIS profiles as a growth stock while SNY is a mature play — different risk/reward profiles.

NBIS carries more volatility with a beta of 1.24 — expect wider price swings.

NBIS is growing revenue faster at 621.0% — sustainability is the question.

SNY generates stronger free cash flow (1.7B), providing more financial flexibility.

Bottom Line

NBIS scores higher overall (53/100 vs 51/100), backed by strong 93.1% margins and 621.0% revenue growth. SNY offers better value entry with a 24.9% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Nebius Group N.V.

COMMUNICATION SERVICES · INTERNET CONTENT & INFORMATION · USA

Nebius Group N.V. (Ticker: NBIS) is a forward-looking technology company specializing in advanced digital solutions designed to enhance client engagement and streamline operational efficiency across diverse sectors. By harnessing the power of cloud computing, artificial intelligence, and data analytics, Nebius equips businesses to effectively manage the complexities of the digital age. With a strong portfolio of intellectual property and meaningful strategic partnerships, the company is poised to capture significant growth opportunities in the dynamic technology landscape, positioning itself as an appealing investment choice for institutional investors seeking high-growth prospects in tech-driven markets.

Visit Website →

Sanofi ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.

Want to dig deeper into these stocks?